# Clinical Trial to Evaluate the Effects of Letermovir Prophylaxis on T-cell Immune Activation in Participants With Treated HIV-1 Infection

> **NCT06626555** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University College, London** · enrollment: 36 (estimated)

## Conditions studied

- HIV

## Interventions

- **DRUG:** Letermovir

## Key facts

- **NCT ID:** NCT06626555
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2024-10-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06626555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06626555, "Clinical Trial to Evaluate the Effects of Letermovir Prophylaxis on T-cell Immune Activation in Participants With Treated HIV-1 Infection". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT06626555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*